Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

  Homepage
Continue on the current website:  

 

ClearRead CT Detect/Compare

See Clearly. Decide Confidently. Reduce nodule search time, increase confidence, and improve detection during search by suppressing normal structures.

Inquire Now

Riverain Technologies
  • CT
  • Analysis
  • Lung Nodules

In a typical CT study, lung nodules and abnormalities are often shielded by physical structures and even machine "noise." ClearRead CT helps the normal be clear and abnormal stand out.

Riverain's ClearRead CT suppression technology simply allows radiologists to tackle a heavy workload with significant time constraints. The ClearRead algorithm is effective at supporting the visualization and detection of solid, part-solid and ground glass nodules.

yellow arrow

~29% improved nodule detection1

1American Journal of Roentgenology. 2018;210: 480-488. 10.2214/AJR.17.18718. Retrieved on March 27, 2023, from https://www.ajronline.org/doi/10.2214/AJR.17.18718

arrow image

26% faster nodule search time1

1American Journal of Roentgenology. 2018;210: 480-488. 10.2214/AJR.17.18718

arrow image

Reduce interoperator variability with ClearRead CT Detect/Compare1

1Manual nodule detection is a task associated with interoperator variability. With ClearRead CT Detect/Compare, interreader-agreement is improved.

 

    Concurrent Reading Enhances Workflow

    Concurrent Reading Enhances Workflow

    ClearRead CT is an FDA-cleared device to support concurrent reading, allowing for faster reading with proven, superior (as compared to readers not aided by ClearRead CT), automatic nodule detection performance for all nodule types, including solid, sub-solid and ground-glass nodules.

    Automated Detection Can Reduce Variability

    Automated Detection Can Reduce Variability

    After the vessels have been suppressed, ClearRead CT Detect/Compare leverages the vessel-suppression series to locate and characterize suspected nodules, enabling transparent, consistent automatic measurements.

    ClearRead CT Compare

    ClearRead CT Compare

    Aids radiologists in tracking finding changes over time.

    References

    References

    1. Lo et al, Computer-Aided Detection of Lung Nodules, AJR, 2018
    2. LB-1174-W ClearRead CT Physician's Training Manual
    3. AR V28N7 Impact of Vessel Suppressed-CT K. Martini MD eta! July 2021
    4. Han et al, Influence of lung nodule margin on volume- and diameter. Br J Radiol, 2018
    5. Martini et al, Impact of Vessel Supressed-CT, Academic Radiology, 2021
    6. Al Central, ClearRead CT Overview, aicentral.acrdsi.org/ProductDetails/16 accessed 29/04/2022

    What Customers Are Saying

    The application enables identification of small nodules faster and more reliably, particularly for oncological patients.

    Terrence Matalon
    MD, Chairman, Diagnostic Radiology at Einstein Medical Center

    May not reflect a typical user experience; actual results may vary.

    What Customers Are Saying

    ClearRead CT technology has helped us to detect lung nodules that may have otherwise been missed."

    Jared Christensen
    MD MBA Card, Cardiothoracic Imaging at Duke University Medical Center

    May not reflect a typical user experience; actual results may vary.
    Dr. Christensen is a paid consultant of Riverain

      References

      1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

      2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

      Legal Mentions

      1. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming

      2. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Magna aliquam erat volutpat tempo molestie vesse

      Request a demo

      See Ahead for Yourself

      Inquire now
      LinkedIn LinkedIn
      Alt tag

      © 2024 Bayer

      The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

      BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners.

      This is intended to provide information for healthcare professionals and other relevant decision makers in the US, European Union, United Kingdom and Switzerland. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

       

      Calantic is ISO 27001 certified. The product Calantic Viewer has CE marking (CE2797). Complies with medical device legislation. Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information. The operating instructions of the product Calantic Viewer can be found on https://www.radiology.bayer.com/manuals

       

      You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

      Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

       

      Last Updated: April 2024

      Bayer Logo